Home / ASX / IPO Watch: Battery listings soar, biotechs take a backseat

IPO Watch: Battery listings soar, biotechs take a backseat

Check out the upcoming IPOs
ASX

While the crisis in Ukraine enters its fourth month, the knock-on effect caused by supply disruptions to energy and commodity prices has been a positive windfall for companies listing in April. In total there were 13 companies that listed on the ASX, with the majority being either energy- or materials-focused, in particular, battery minerals (lithium) explorers.

IPO watch – April

Most interest was in the Firetail Resources (ASX: FTL) IPO. On the day of listing, the battery minerals explorer finished up 46% to 36.5 cents. Shares hit a high of 38.5 cents, giving investors a cool 54% gain for the day. Firetail has an extensive battery-metal-focused portfolio of exploration assets across Australia which include the Yalgoo lithium project and Mt Slopeaway nickel, cobalt and rubidium project in Queensland. In the raising, it secured investment from a Chinese battery materials company, Shanghai Jayson New Energy Materials (Jayson).

  • International Graphite (ASX:IG6) was the best performing IPO for April, its shares listing at 20c rising to 44c. That’s a rise of 120 per cent since 5 April. It aims to develop its first fully-integrated graphite production facility to supply anode material to meet the growing international demand for lithium-based batteries.

    IPO watch – Upcoming IPOs

    Chrysos IPO

    Booked in for 6 May is the biggest IPO of the year, gold testing business Chrysos Corporation (ASX:C79). The company manufactures gold assay machines employing its PhotonAssay intellectual property, which is said to be the most innovative and valuable assaying solution available. According to the company it works by “hitting samples with high-energy X-rays, Chrysos PhotonAssayâ„¢ technology causes excitation of atomic nuclei allowing enhanced analysis of gold, silver and complementary elements in as little as two minutes.” This allows “faster, safer, and more accurate gold analysis.”

    According to the Australian Financial Review, lead manager Barrenjoey set the IPO price at $6.50 a share, valuing the company at $535 million on an enterprise value basis and $637 million in terms of market capitalisation. The capital raising is for $180 million.

    M&A Activity during 1Q22

    According to the HLB Mann Judd Australian M&A activity for Q2 2022 report, the number of M&A transactions completed in Australia dropped, while the average deal value increased significantly compared to the prior year. There were 334 deals completed compared to 351 in Q2 FY2021, being a decrease of 5% with the average deal rising to $129m from $92m in Q2 FY2021 to Q2 FY2022.

    Here were the major deals in Q2 – listed by transaction value

    Ishan Dan

    Ishan is an experienced journalist covering The Inside Investor and The Insider Adviser publications.




    Print Article

    Related
    Lifestyle Communities falls foul of soft Victorian housing market

    A developer of downsizer-centric homes across Victoria has struggled to get investor interest in the face of the state’s struggling economy. A negative media report highlighting residents’ complaints about fees hasn’t helped.

    Jamie Nemtsas | 23rd Apr 2025 | More
    Long-suffering Iress shareholders get shot in the arm with 10c dividend

    Like the curate’s egg, the markets software group’s investment story is good in part. While the 2024 full-year result was a marked improvement compared with 2023, investors don’t need reminding the share price has retreated over the past five years.

    Jamie Nemtsas | 15th Apr 2025 | More
    Medibank Private to encounter strong political headwinds

    The private health insurer delivered a healthy first-half result, with its net profit up 14 per cent to $299 million. Policies emanating out of Canberra could play a big part on how well it builds on that number in the second half.

    Jamie Nemtsas | 9th Apr 2025 | More
    Popular